Logo
x

Search

Subscribe Now

bridgebio

BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease

BridgeBio’s BBP-812 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for Canavan Disease

  • September 11, 2024
bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy

bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy

  • January 11, 2024
BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hyperplasia

BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hy...

  • October 5, 2023
BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023

BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023

  • August 28, 2023
BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type A

BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type...

  • August 12, 2022
BridgeBio Reports Results of BBP-812 in the P-I/II (CANaspire) Trial for the Treatment of Canavan Disease

BridgeBio Reports Results of BBP-812 in the P-I/II (CANaspire) Trial for the Treatment of Canavan Disease

  • June 23, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.